CLINICAL TRIALS PROFILE FOR ALMOTRIPTAN MALATE
✉ Email this page to a colleague
All Clinical Trials for ALMOTRIPTAN MALATE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00210483 ↗ | A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents | Completed | Ortho-McNeil Neurologics, Inc. | Phase 3 | 2003-07-01 | The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate (AXERT®) in treating acute migraine headaches in adolescents. Amotriptan malate (AXERT®) is approved for use in the treatment of acute migraine headache with or without aura in adults. In this study, adolescents will be given a single dose of study medication to treat one migraine headache. |
NCT00210483 ↗ | A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents | Completed | Janssen-Ortho LLC | Phase 3 | 2003-07-01 | The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate (AXERT®) in treating acute migraine headaches in adolescents. Amotriptan malate (AXERT®) is approved for use in the treatment of acute migraine headache with or without aura in adults. In this study, adolescents will be given a single dose of study medication to treat one migraine headache. |
NCT00210496 ↗ | Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 4 | 2005-06-01 | The purpose of this study is to evaluate the impact of topiramate (migraine prevention medicine) on the effectiveness of almotriptan malate (acute migraine medicine) when treating acute migraine headaches. |
NCT00210496 ↗ | Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine | Completed | Janssen-Ortho LLC | Phase 4 | 2005-06-01 | The purpose of this study is to evaluate the impact of topiramate (migraine prevention medicine) on the effectiveness of almotriptan malate (acute migraine medicine) when treating acute migraine headaches. |
NCT00210509 ↗ | A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache | Completed | Ortho-McNeil Neurologics, Inc. | Phase 4 | 2004-11-01 | The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate (AXERT®) 12.5 milligram tablets compared with placebo for the acute treatment of migraine headache at the earliest onset of headache pain. Almotriptan malate (AXERT®) is approved for the treatment of migraine headache, with or without aura, in adults. Patients in this study will take either almotriptan or placebo oral tablets for 3 consecutive migraine headaches. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ALMOTRIPTAN MALATE
Condition Name
Clinical Trial Locations for ALMOTRIPTAN MALATE
Trials by Country
Clinical Trial Progress for ALMOTRIPTAN MALATE
Clinical Trial Phase
Clinical Trial Sponsors for ALMOTRIPTAN MALATE
Sponsor Name